HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma

Journal of Thoracic Oncology

Volumn 9, Issue 3, 2014, Pages 419-422

  Hong, Mineui ^a   Kim, Ryong Nam ^b   Song, Ji Young ^a   Choi, So Jung ^a   Oh, Ensel ^a   Lira, Maruja E ^c   Mao, Mao ^c   Takeuchi, Kengo ^d   Han, Joungho ^a   Kim, Jhingook ^a   Choi, Yoon La ^a,e  

^a Samsung Medical Center   (South Korea)

^b Seoul National University   (South Korea)

^c PFIZER INC   (United States)

^d CANCER INSTITUTE   (Japan)

^e Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Anaplastic lymphoma kinase; HIP1; Lung cancer; Translocation

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; HUNTINGTIN INTERACTING PROTEIN 1; HYBRID PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CHROMOSOME TRANSLOCATION; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE SEQUENCE; GENETIC TRANSCRIPTION; HUMAN; LUNG ADENOCARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS;

ADENOCARCINOMA; ADULT; CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; ONCOGENE PROTEINS, FUSION; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84894596882     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000061     Document Type: Article

References (12)

1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566.
2. Sasaki T, Rodig SJ, Chirieac LR, Jänne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010;46:1773-1780.
3. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-1203.
4. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009;15:3143-3149.
5. Togashi Y, Soda M, Sakata S, et al. KLC1-ALK: A novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One 2012;7:e31323.
6. Jung Y, Kim P, Jung Y, et al. Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing. Genes Chromosomes Cancer 2012;51:590-597.
7. Kalchman MA, Koide HB, McCutcheon K, et al. HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-Associated huntingtin in the brain. Nat Genet 1997;16:44-53.
8. Itoh T, Koshiba S, Kigawa T, Kikuchi A, Yokoyama S, Takenawa T. Role of the ENTH domain in phosphatidylinositol-4,5-bisphosphate binding and endocytosis. Science 2001;291:1047-1051.
9. Rao DS, Hyun TS, Kumar PD, et al. Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. J Clin Invest 2002;110:351-360.
10. Ross TS, Bernard OA, Berger R, Gilliland DG. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7) (q33;q11.2). Blood 1998;91:4419-4426.
11. Li R, Morris SW. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev 2008;28:372-412.
12. Mano H. Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci 2008;99:2349-2355.